Progression in patients with low- and intermediate1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
A high proportion of patients with lower-risk del(5q) myelodysplastic syndromes (MDS) will respond to treatment with lenalidomide. Median duration of transfusion-independence is 2 years with some long-lasting responses, but almost 40% of patients progress to acute leukemia by 5 years after start of...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
Ferrata Storti Foundation
2016
|